We are focused on drug discovery at unprecedented speed and scale, with lower risk and higher certainty across multiple diseases in parallel.
Palo Alto, California
Joined November 2020
- Tweets85
- Following53
- Followers417
- Likes123
Pinned Tweet
🌟 An update on our exciting progress in learning and predicting the effects of small molecules on the transcriptome! 🌟
transcriptabio.com/post/mast…
Today, we announced a research collaboration and licensing agreement with @MayoClinic to advance the discovery of new treatments for amyotrophic lateral sclerosis (ALS).
news.transcriptabio.com/p/tr…
Today we announced results from our research collaboration with @SynfiniInc, which produced a validated-quality lead candidate targeting MSH3, a gene increasingly understood to drive the progression of Huntington’s disease, in just a few weeks.
news.transcriptabio.com/p/tr…
As part of @Nature’s @bpdealmakers, Transcripta Bio was featured for its pioneering work in AI-powered innovation for drug discovery.
#TranscriptaBio #Biopharmadealmakers #Innovation
nature.com/articles/d43747-0…
Characterizing collections of molecules is an important chemoinformatics task. Beyond annotating molecules by common descriptors, can we gain insight by leveraging LLMs for initial triage? Our prototype app, MolSifter, does just that!
We've been using NVIDIA's MolMIM model — guided by our own perturbation predictions — to generate molecules with specific effects on gene expression. LLMs help by 1) orienting us to interesting patterns in a collection and 2) enabling chat-based analysis to gain deeper insight.
We were honored to invite @ashleevance to Transcripta Bio to share our story and how we are charting a faster path in drug discovery to create better lives for people around the world.
bloomberg.com/news/articles/…
Our Director of Software Engineering, Clayton Mellina, believes a patient-centered approach, coupled with breakthrough technologies in machine learning and high-throughput biology, will drive a revolution in human health.
Read more of our conversation: rarebase.org/post/unleashing…
Rarebase has generated a premier drug screening dataset that maximizes efficiency in drug hunting for rare neurological diseases.
Learn more about our breakthrough approach to meet the urgent needs of the #raredisease patient community: rarebase.org/post/how-the-ra…
In our latest podcast, Director of High Throughput Biology, Joe Bellucci, PhD, walks us through advances in high-throughput screening and next-generation sequencing that have enabled tailored and scalable approaches to rare disease research. Listen here: spotifyanchor-web.app.link/e…
Neurodevelopmental disorders make up 77% of our current drug discovery portfolio.
This National Developmental Disabilities Awareness Month, let's champion support & inclusion for affected individuals with the rare disease community. #DDAM2023
Join us in recognizing #CACNA1A Awareness Day on March 19th!
At Rarebase, we partner with the patient organization Miren's Marathon at the Rare Village Foundation in support of those affected by CACNA1A-related conditions. Together, we build a path forward for rare diseases.
Our discovery research team has been gearing up for compound testing in our Preclinical Stage!
Our wild-type stem cells are thawed and ready for expansion and differentiation into neurons for concentration-response studies with Function-identified drug repurposing candidates.
We sat down with our Scientific Founder and Advisor, Elizabeth Iorns, PhD, to dive into the science and technology behind the Rarebase drug discovery strategy.
Read more here: rarebase.org/post/reimaginin…
At Rarebase, we are filling the void in rare disease drug discovery to meet the urgent unmet needs of the rare disease community. This #RareDiseaseDay, learn how our precision medicine platform is advancing the hunt for new therapies: rarebase.org/post/3-700-dise…
We are committed to making a difference in the lives of those affected by rare diseases and we look forward to supporting #RareDiseaseDay next week. Sign up for our newsletter to follow our journey: eepurl.com/hKNGWr
Tomorrow is International Day of Women and Girls in Science 🧬🔬🚀
We are grateful to all the women on the Rarebase team for your tireless work to foster partnerships with patient organizations and drive our precision medicine research forward for the #raredisease community.
Transcripta Bio retweeted
Honored to be working with @cureSYNGAP1 on drug discovery for SYNGAP1 related disorders with @rarebasepbc. Thanks @JMGraglia and @SYNGAP1mom for all you do for the community!
Read & share this @Newsweek story profiling SRF, our founders (@SYNGAP1mom & @JMGraglia) and Tony's diagnostic journey.
newsweek.com/my-son-syngap1-…
FYI @StanfordChild @IDreamofGenes @Invitae @Labcorp (MNG)
Our #precisionmedicine platform Function identifies #drugrepurposing candidates that have the potential to target the root cause biology of rare genetic diseases. Discover how we identify these candidates based on common types of genetic variants: rarebase.org/post/how-does-r…
